Literature DB >> 20836136

Cerebrospinal fluid tau and phosphorylated tau protein are elevated in corticobasal syndrome.

M B Aerts1, R A J Esselink, B R Bloem, M M Verbeek.   

Abstract

Differentiating corticobasal syndrome (CBS) from progressive supranuclear palsy (PSP) and idiopathic Parkinson's disease (PD) can be difficult. To investigate the additional value of cerebrospinal fluid (CSF) biomarkers in the diagnostic differentiation of parkinsonism, we analyzed the CSF concentrations of total protein, lactate and brain specific proteins amyloid-β(42) protein, tau protein (t-tau), and tau protein phosphorylated at Thr181 (p-tau), in CSF samples from patients with PSP (n = 21), CBS (n = 12), and PD (n = 28). CBS patients demonstrated higher concentrations of t-tau and p-tau compared with PSP and PD patients. In discriminating CBS and PD, t-tau offered the best combination of sensitivity (75%) and specificity (90.9%), followed by p-tau (sensitivity 87.5% and specificity 75%). The p-tau/t-tau ratio resulted in sensitivity of 84.2% and specificity of 66.7% in discriminating PSP and CBS. In conclusion, our results suggest that CSF parameters are of additional value in the diagnostic differentiation of CBS and PD.
Copyright © 2010 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20836136     DOI: 10.1002/mds.23341

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  12 in total

1.  In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET.

Authors:  Akio Kikuchi; Nobuyuki Okamura; Takafumi Hasegawa; Ryuichi Harada; Shoichi Watanuki; Yoshihito Funaki; Kotaro Hiraoka; Toru Baba; Naoto Sugeno; Ryuji Oshima; Shun Yoshida; Junpei Kobayashi; Michinori Ezura; Michiko Kobayashi; Ohito Tano; Shunji Mugikura; Ren Iwata; Aiko Ishiki; Katsutoshi Furukawa; Hiroyuki Arai; Shozo Furumoto; Manabu Tashiro; Kazuhiko Yanai; Yukitsuka Kudo; Atsushi Takeda; Masashi Aoki
Journal:  Neurology       Date:  2016-10-28       Impact factor: 9.910

2.  Aβ1-15/16 as a potential diagnostic marker in neurodegenerative diseases.

Authors:  Magdalena Nutu; Philippe Bourgeois; Henrik Zetterberg; Erik Portelius; Ulf Andreasson; Stéphane Parent; Francesco Lipari; Sara Hall; Radu Constantinescu; Oskar Hansson; Kaj Blennow
Journal:  Neuromolecular Med       Date:  2012-12-07       Impact factor: 3.843

3.  Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis.

Authors:  Murray Grossman; Lauren Elman; Leo McCluskey; Corey T McMillan; Ashley Boller; John Powers; Katya Rascovsky; William Hu; Les Shaw; David J Irwin; Virginia M-Y Lee; John Q Trojanowski
Journal:  JAMA Neurol       Date:  2014-04       Impact factor: 18.302

Review 4.  New insights into atypical parkinsonism.

Authors:  Gregor K Wenning; Florian Krismer; Werner Poewe
Journal:  Curr Opin Neurol       Date:  2011-08       Impact factor: 5.710

Review 5.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505

6.  A Panel of Plasma Biomarkers for Differential Diagnosis of Parkinsonian Syndromes.

Authors:  Qi Li; Zhen Li; Xiaoxuan Han; Xiao Shen; Fei Wang; Lipeng Bai; Zhuo Li; Rui Zhang; Yanlin Wang; Xiaodong Zhu
Journal:  Front Neurosci       Date:  2022-02-17       Impact factor: 4.677

7.  Temporal Progression Patterns of Brain Atrophy in Corticobasal Syndrome and Progressive Supranuclear Palsy Revealed by Subtype and Stage Inference (SuStaIn).

Authors:  Yuya Saito; Koji Kamagata; Peter A Wijeratne; Christina Andica; Wataru Uchida; Kaito Takabayashi; Shohei Fujita; Toshiaki Akashi; Akihiko Wada; Keigo Shimoji; Masaaki Hori; Yoshitaka Masutani; Daniel C Alexander; Shigeki Aoki
Journal:  Front Neurol       Date:  2022-02-25       Impact factor: 4.086

8.  Parkinson's Disease Diagnostic Observations (PADDO): study rationale and design of a prospective cohort study for early differentiation of parkinsonism.

Authors:  Anouke van Rumund; Marjolein B Aerts; Rianne A J Esselink; Frederick J A Meijer; Marcel M Verbeek; Bastiaan R Bloem
Journal:  BMC Neurol       Date:  2018-05-16       Impact factor: 2.474

9.  Plasma Biomarkers Differentiate Parkinson's Disease From Atypical Parkinsonism Syndromes.

Authors:  Chin-Hsien Lin; Shieh-Yueh Yang; Herng-Er Horng; Che-Chuan Yang; Jen-Jie Chieh; Hsin-Hsien Chen; Bing-Hsien Liu; Ming-Jang Chiu
Journal:  Front Aging Neurosci       Date:  2018-04-27       Impact factor: 5.750

10.  MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology.

Authors:  Chihiro Sato; Nipun Mallipeddi; Nupur Ghoshal; Brenton A Wright; Gregory S Day; Albert A Davis; Albert H Kim; Gregory J Zipfel; Randall J Bateman; Audrey Gabelle; Nicolas R Barthélemy
Journal:  Ann Clin Transl Neurol       Date:  2021-08-02       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.